text
"['\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2024년 06월 30일\n)\n(단위 : 백만원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nHPI, INC.\n비상장\n2007.09.14\n해외임상시험\n187\n200,200\n100.00\n75\n-\n-\n-\n200,200\n100.00\n75\n721\n265\nImmunoMet Therapeutics, Inc\n비상장\n2015.08.24\n투자\n4,178\n1,285,412\n15.95\n2,701\n-\n-\n-\n1,285,412\n15.95\n2,701\n3,088\n-1,720\nImmunovant, Inc.\n상장\n2019.01.11\n투자\n5,609\n939,395\n0.65\n51,030\n-\n-\n-16,578\n939,395\n0.65\n34,452\n819\n-118\nNurron Pharmaceuticals, Inc\n비상장\n2021.07.19\n공동연구 추진\n571\n58,343\n2.21\n571\n-\n-\n-\n58,343\n2.21\n571\n2,273\n-693\nAlloplex Biotherapeutics Inc.\n비상장\n2021.07.29\n투자\n788\n9,793\n0.38\n788\n-\n-\n-\n9,793\n0.38\n788\n4,810\n-1,069\n대웅인베스트먼트 바이오투자조합1호\n비상장\n2023.07.21\n투자\n1,000\n5,000\n25.00\n1,000\n-\n-\n-\n5,000\n25.00\n1,000\n3,683\n-242\nFreemind Investments L.P.(*)\n비상장\n2023.05.31\n투자\n661\n-\n-\n661\n-\n-\n-\n-\n-\n661\n2,611\n-\nInteron Laboratires, Inc(*)\n비상장\n2023.01.20\n투자\n618\n-\n-\n618\n-\n-\n-\n-\n-\n618\n4,622\n-1,834\nTurnBio technologies, Inc.\n비상장\n2022.04.01\n투자\n1,565\n1,466,072\n2.52\n1,643\n2,331,817\n2,729\n-\n3,797,889\n6.34\n4,372\n7,791\n-7,644\n차세대 지역 뉴딜&바이오투자조합(*)\n비상장\n2022.11.01\n투자\n700\n700\n5.00\n700\n-\n-\n-\n700\n5.00\n700\n13,599\n-478\n합 계\n3,964,915\n-\n59,787\n2,331,817\n2,729\n-16,578\n6,296,732\n-\n45,938\n44,017\n-13,533\n(*)\n재무현황은 23년 기말 재무제표 기준입니다.\n']"
